MEGIN
  • About us
  • MEG Maps™
  • Insights & Education
    • News
    • MEGIN Spotlights
    • MEGIN Masterclass
    • Abstracts & Studies
  • Patients
  • Find a MEG site
    • Global
    • North America
  • Contact us
  • 🇨🇳
Select Page
MEGIN CEO Speaks at Neuroscience-20 World Brain Mapping Summit in Argentina

MEGIN CEO Speaks at Neuroscience-20 World Brain Mapping Summit in Argentina

by MEGIN | Dec 6, 2018 | MEGIN News

MEGIN CEO Speaks at Neuroscience-20 World Brain Mapping Summit in Argentina BUENOS AIRES, Argentina, Dec. 6, 2018 — Janne Huhtala, CEO of MEGIN, a manufacturer of magnetoencephalography (MEG) technology for functional brain imaging, spoke about the future...
Le Bonheur Children’s Is First In The World To Install TRIUX™ neo For Functional Brain Imaging

Le Bonheur Children’s Is First In The World To Install TRIUX™ neo For Functional Brain Imaging

by MEGIN | Sep 26, 2018 | MEGIN News

Click here to see the entire original article.   “MEMPHIS, Tenn., Sept. 26, 2018/PRNewswire/ –MEGIN announced today Le Bonheur Children’s Hospital is the first hospital in the world to install TRIUX™ neo, the next generation of...
The University of Oxford is the First In Europe to Aquire Latest MEG Technology from MEGIN

The University of Oxford is the First In Europe to Aquire Latest MEG Technology from MEGIN

by MEGIN | Feb 18, 2018 | MEGIN News

OXFORD, UNITED KINGDOM (February 08, 2019) – MEGIN is pleased to announce that the University of Oxford is the first in Europe to acquire the latest technology in functional brain imaging. TRIUX™ neo, a magnetoencephalograph (MEG), is a highly sensitive non-invasive...
Next Entries »

Home
About us
MEG Maps™
Careers
Contact us
Join Our Mailing List

Insights & education
News
MEGIN Spotlights
MEGIN Masterclass
Abstracts & studies

Patients

Find a MEG site
Global
North America

Connect with us
  • Follow
  • Follow
  • Follow

Copyright 2025© – MEGIN
MEGIN’s new platform MEG Maps™ is powered by TRIUX™ neo and MEGreview™, which have 510(k) clearance from the US Food & Drug Administration (FDA) and are under EU MDR Notified body review, i.e. not available for commercial distribution in the EU area. For commercial distribution, please contact your local MEGIN representative. TRIUX™ neo is intended to non-invasively record brain activity, and when interpreted by trained physicians, to help localize these active areas. All other applications are scientific research in nature. Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.

Subscribe to MEGIN Matters

Don’t miss the latest MEG insights and MEGIN news – complete the form below to be added to our mailing list and receive MEGIN Matters right in your inbox!